Tarun Kumar Dutta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tarun Kumar Dutta has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bethi
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
1 shared publication Chanaveerappa Bammigatti
Affiliation Department of Medicine, Jawaharlal Institute of Medical Education and Research, Puducherry, India
1 shared publication- Debdatta Basu
Department of Pathology, JIPMER, Pondicherry, India
1 shared publication - Gitanjali Batmanabane
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India
1 shared publication - Hemant Deepak Shewade
Division of Health Systems Research, ICMR National Institute of Epidemiology (ICMR-NIE), Chennai, India
1 shared publication - Maya Gopalakrishnan
Department of Medicine, All India Institute of Medical Sciences , Jodhpur
1 shared publication
Latest Publications
- Open Access
- 22 February 2022
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 16 (2) , e0010183
A simple mortality risk prediction score for viper envenoming in India (VENOMS): A model development and validation study
Background: Snakebite is a neglected problem with a high mortality in India. There are no simple clinical prognostic tools which can predict mortality in viper envenomings. We aimed to develop and validate a mortality-risk prediction score for patients of viper envenoming from Southern India. Methods: We used clinical predictors from a prospective cohort of 248 patients with syndromic diagnosis of viper envenoming and had a positive 20-minute whole blood clotting test (WBCT 20) from a tertiary-care hospital in Puducherry, India. We applied multivariable logistic regression with backward elimination approach. External validation of this score was done among 140 patients from the same centre and its performance was assessed with concordance statistic and calibration plots. Findings: The final model termed VENOMS from the term “Viper ENvenOming Mortality Score included 7 admission clinical parameters (recorded in the first 48 hours after bite): presence of overt bleeding manifestations, presence of capillary leak syndrome, haemoglobin 6.5 h, systolic blood pressure < 100 mm Hg, urine output <20 mL/h in 24 h and female gender. The lowest possible VENOMS score of 0 predicted an in-hospital mortality risk of 0.06% while highest score of 12 predicted a mortality of 99.1%. The model had a concordance statistic of 0·86 (95% CI 0·79–0·94) in the validation cohort. Calibration plots indicated good agreement of predicted and observed outcomes. Conclusions: The VENOMS score is a good predictor of the mortality in viper envenoming in southern India where Russell’s viper envenoming burden is high. The score may have potential applications in triaging patients and guiding management after further validation.
- 22 February 2022
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 16 (2) , e0010183
Open AccessA simple mortality risk prediction score for viper envenoming in India (VENOMS): A model development and validation study
Background: Snakebite is a neglected problem with a high mortality in India. There are no simple clinical prognostic tools which can predict mortality in viper envenomings. We aimed to develop and validate a mortality-risk prediction score for patients of viper envenoming from Southern India. Methods: We used clinical predictors from a prospective cohort of 248 patients with syndromic diagnosis of viper envenoming and had a positive 20-minute whole blood clotting test (WBCT 20) from a tertiary-care hospital in Puducherry, India. We applied multivariable logistic regression with backward elimination approach. External validation of this score was done among 140 patients from the same centre and its performance was assessed with concordance statistic and calibration plots. Findings: The final model termed VENOMS from the term “Viper ENvenOming Mortality Score included 7 admission clinical parameters (recorded in the first 48 hours after bite): presence of overt bleeding manifestations, presence of capillary leak syndrome, haemoglobin 6.5 h, systolic blood pressure < 100 mm Hg, urine output <20 mL/h in 24 h and female gender. The lowest possible VENOMS score of 0 predicted an in-hospital mortality risk of 0.06% while highest score of 12 predicted a mortality of 99.1%. The model had a concordance statistic of 0·86 (95% CI 0·79–0·94) in the validation cohort. Calibration plots indicated good agreement of predicted and observed outcomes. Conclusions: The VENOMS score is a good predictor of the mortality in viper envenoming in southern India where Russell’s viper envenoming burden is high. The score may have potential applications in triaging patients and guiding management after further validation.
- Open Access
- 19 July 2017
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 25 (6) , 317-321
Prevalence and predictors of potential drug–drug interactions in patients of internal medicine wards of a tertiary care hospital in India
Background Drug–drug interactions are a major source of adverse drug events (ADEs). Polypharmacy, age and the number of comorbid conditions are important predictors of adverse drug interactions. ADEs account for up to 5% of hospital admissions per year and an increase in the length of hospital stay. Objective To find the prevalence and predictors of potential drug–drug interactions (pDDIs) in patients admitted to the wards of an internal medicine department of a tertiary care hospital. Method Patients admitted to internal medicine wards with prescriptions having more than one drug were selected. Demographic details including age, gender, number of comorbid conditions, number of drugs prescribed and the disease for which the patient was admitted were recorded in a case record form. Interactions were checked using Micromedex DrugReax software. Results A total of 939 patients were recruited for this study based on inclusion criteria. 433 prescriptions (46%) had one or more pDDIs, with a range of 1–13 drug interactions per prescription. A total of 1395 drug interactions were found, with 866 moderate drug interactions (62%), 435 major interactions (31.1%) and 89 minor interactions (6.3%). During the study period only three contraindicated drug combinations (0.2%) were recorded. A significant association (p6 drugs are at major risk for occurrence of pDDIs. Moderate severity interactions were the highest number followed by major severity interactions.
- 19 July 2017
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 25 (6) , 317-321
Open AccessPrevalence and predictors of potential drug–drug interactions in patients of internal medicine wards of a tertiary care hospital in India
Background Drug–drug interactions are a major source of adverse drug events (ADEs). Polypharmacy, age and the number of comorbid conditions are important predictors of adverse drug interactions. ADEs account for up to 5% of hospital admissions per year and an increase in the length of hospital stay. Objective To find the prevalence and predictors of potential drug–drug interactions (pDDIs) in patients admitted to the wards of an internal medicine department of a tertiary care hospital. Method Patients admitted to internal medicine wards with prescriptions having more than one drug were selected. Demographic details including age, gender, number of comorbid conditions, number of drugs prescribed and the disease for which the patient was admitted were recorded in a case record form. Interactions were checked using Micromedex DrugReax software. Results A total of 939 patients were recruited for this study based on inclusion criteria. 433 prescriptions (46%) had one or more pDDIs, with a range of 1–13 drug interactions per prescription. A total of 1395 drug interactions were found, with 866 moderate drug interactions (62%), 435 major interactions (31.1%) and 89 minor interactions (6.3%). During the study period only three contraindicated drug combinations (0.2%) were recorded. A significant association (p6 drugs are at major risk for occurrence of pDDIs. Moderate severity interactions were the highest number followed by major severity interactions.
- Open Access
- 19 January 2016
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 32 (4) , 418-423
Proliferation and Angiogenesis Using Immunohistochemistry in Prognosticating Multiple Myeloma
Multiple myeloma is a neoplasm of plasma cells characterised by the presence of M protein in serum and urine. Angiogenesis and proliferation play a major role in the pathogenesis of various neoplasms. The study evaluated proliferation and angiogenesis in 48 cases of myeloma, and correlated it with morphological and clinical parameters. The histomorphological features like plasma cell morphology, percentage of plasma cells and pattern of infiltration were studied in the bone marrow aspirate and trephine biopsy. Angiogenesis was assessed by calculating the microvessel density (MVD) using immunohistochemistry for CD34. Proliferation was assessed using Ki67 and CD38 highlighted the plasma cells. The mean Ki67 % was found to be significantly higher (19.6 % range 2–40 %) in poorly differentiated morphology compared to well differentiated morphology (4.06 % range 0.2–20 %) (p = 0.003). The mean MVD in the well differentiated morphology was 10.6 (range 1.2–47.4) compared to 20.3 (range 6.9–39.6) in the poorly differentiated morphology (p = 0.04). The mean MVD was 5.7 (range 1.2–12.8) in the interstitial pattern of infiltration compared to 20.04 (2.9–47.4) in the diffuse pattern (p < 0.0001). The mean MVD was 6.4 in cases with serum albumin >3.5 gm/dl compared to 13.3 in cases with serum albumin p = 0.009). Both the Ki67 and MVD showed an increasing trend with the clinical staging. Thus the study of proliferation and angiogenesis in bone marrow biopsy is useful for prognosticating patients with multiple myeloma.
- 19 January 2016
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 32 (4) , 418-423
Open AccessProliferation and Angiogenesis Using Immunohistochemistry in Prognosticating Multiple Myeloma
Multiple myeloma is a neoplasm of plasma cells characterised by the presence of M protein in serum and urine. Angiogenesis and proliferation play a major role in the pathogenesis of various neoplasms. The study evaluated proliferation and angiogenesis in 48 cases of myeloma, and correlated it with morphological and clinical parameters. The histomorphological features like plasma cell morphology, percentage of plasma cells and pattern of infiltration were studied in the bone marrow aspirate and trephine biopsy. Angiogenesis was assessed by calculating the microvessel density (MVD) using immunohistochemistry for CD34. Proliferation was assessed using Ki67 and CD38 highlighted the plasma cells. The mean Ki67 % was found to be significantly higher (19.6 % range 2–40 %) in poorly differentiated morphology compared to well differentiated morphology (4.06 % range 0.2–20 %) (p = 0.003). The mean MVD in the well differentiated morphology was 10.6 (range 1.2–47.4) compared to 20.3 (range 6.9–39.6) in the poorly differentiated morphology (p = 0.04). The mean MVD was 5.7 (range 1.2–12.8) in the interstitial pattern of infiltration compared to 20.04 (2.9–47.4) in the diffuse pattern (p < 0.0001). The mean MVD was 6.4 in cases with serum albumin >3.5 gm/dl compared to 13.3 in cases with serum albumin p = 0.009). Both the Ki67 and MVD showed an increasing trend with the clinical staging. Thus the study of proliferation and angiogenesis in bone marrow biopsy is useful for prognosticating patients with multiple myeloma.